Showing 1581-1590 of 2050 results for "".
- University of Oklahoma Study Identifies 20 Novel Variants for Inherited Retinal Diseaseshttps://modernod.com/news/university-of-oklahoma-study-identifies-20-novel-variants-for-inherited-retinal-diseases/2482824/A new study out of the University of Oklahoma maps 20 new gene mutations contributing to rare inherited retinal diseases (IRDs). Researchers aim to use these findings to improve diagnostic accuracy and identify targets for future
- FDA Approves Genentech’s Susvimo for Diabetic Retinopathyhttps://modernod.com/news/fda-approves-genentechs-susvimo-for-diabetic-retinopathy/2482815/Genentech has received FDA approval for Susvimo (ranibizumab injection) 100 mg/mL for the treatment of diabetic retinopathy (DR). The approval makes Susvimo the first and only FDA-approved continuous delivery treatment shown to maintain vision in people with DR with one refill ever
- Bausch + Lomb Launches Zenlens CHROMA HOA in the UShttps://modernod.com/news/bausch-lomb-launches-zenlens-chroma-hoa-in-the-us/2482802/Bausch + Lomb announced the US launch of Zenlens CHROMA HOA scleral contact lenses. Designed to correct advanced higher-order aberrations (HOA), this custom, wavefront-guided scleral lens technology delivers enhanced vision and improves clarity by reducing symptoms such as halos an
- EyeCool Therapeutics Announces Positive Results from Pilot Study in Patients with Chronic Ocular Surface Pain (COSP)https://modernod.com/news/eyecool-therapeutics-announces-positive-results-from-pilot-study-in-patients-with-chronic-ocular-surface-pain-cosp/2482799/EyeCool Therapeutics announced positive clinical data from a double-masked, randomized controlled pilot study of 31 patients in Australia evaluating the safety and efficacy of its investigational device (ETX-4143) for the treatment of Chronic Ocular Surface Pain (COSP). T
- Bausch + Lomb Receives CE Mark Approval for Preloaded LuxLife Full Range of Vision IOLshttps://modernod.com/news/bausch-lomb-receives-ce-mark-approval-for-preloaded-luxlife-full-range-of-vision-iols/2482789/Bausch + Lomb has received CE Mark approval for the LuxLife full range of vision IOLs. According to B+L, the preloaded IOL provides patients with natural, continuous vision, from distance to near. In a multicenter, comparative clinical study evaluating the LuxLife IOL versus t
- Aldeyra Plans to Resubmit NDA for DED Candidate Reproxalap After Dry Eye Chamber Trial Resultshttps://modernod.com/news/aldeyra-plans-to-resubmit-nda-for-ded-candidate-reproxilap-after-dry-eye-chamber-trial-results/2482788/Aldeyra Therapeutics announced it has achieved the primary endpoint in a phase 3 randomized, double-masked, vehicle-controlled dry eye chamber trial of its investigational drug candidate reproxalap.
- Astellas to Present New Data in Geographic Atrophy at Upcoming Ophthalmology Annual Congresseshttps://modernod.com/news/astellas-to-present-new-data-in-geographic-atrophy-at-upcoming-ophthalmology-annual-congresses/2482775/Astellas Pharma will highlight new data that enhances continued understanding of the science of geographic atrophy (GA), and the experience of patients living with the progressive disease at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO), May 4-8, Salt Lake City, U
- Ace Vision Group Closes $29.4 Million Series B Financing Roundhttps://modernod.com/news/ace-vision-group-closes-294-million-series-b-financing-round/2482767/Ace Vision Group announced the successful close of a $29.4 million Series B financing round. The new capital will support the continued development of the company’s proprietary Gen II VisioLite Ophthalmic Laser, which delivers the minimally invasive LSM procedure—a treatment targ
- First Atropine Eye Drop to Slow Myopia Progression in Children Approved in Indiahttps://modernod.com/news/first-atropine-eye-drop-to-slow-myopia-progression-in-children-approved-in-india/2482750/Entod Pharmaceuticals announced it has received marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO) for the first 0.05% atropine eye drops (Myatro XL) developed to slow the progression of myopia in children age 6 to 12. This milestone foll
- Bausch + Lomb Recycles Over 625,000 Pounds of Eye Care Materialshttps://modernod.com/news/bausch-lomb-recycles-over-625000-pounds-of-eye-care-materials/2482745/Bausch + Lomb announced a sustainability milestone: its 'ONE by ONE' and 'Biotrue Eye Care' recycling programs have collectively diverted more than 103 million units, or 625,026 pounds, of used contact lenses and eye care materials fr